Naltrexone
Research News and Information

Sunday, November 22, 2009

Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.

30 Oct 2009 OBJECTIVE: To determine if topical application of naltrexone hydrochloride (NTX), an opioid antagonist, restores tear production and corneal sensation in rats with diabetes mellitus. METHODS: Type 1 diabetes was induced with streptozotocin in rats. ... Read more...

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.

30 Oct 2009 Preclinical investigations utilizing murine experimental auto-immune encephalomyelitis (EAE), as well as clinical observations in patients with multiple sclerosis (MS), may suggest alteration of endogenous opioid systems in MS. In this study we used ... Read more...

Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion.

30 Oct 2009 BACKGROUND: Methadone is an opioid agonist often given to manage acute and chronic pain. We sought to determine whether methadone compared with morphine dose dependently reduces myocardial infarct size (IS) and whether the mechanism is delta-opioid ... Read more...

Latest indexed articles for 'Naltrexone'

These are the very latest articles for this heading:

• Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. 30 Oct 2009
• Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. 30 Oct 2009
• Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. 30 Oct 2009
• Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. 29 Sep 2009
• The peripheral antinociceptive effects of endomorphin-1 and kynurenic acid in the rat inflamed joint model. 29 Sep 2009
• Long-term use of methylnaltrexone for the management of constipation in advanced cancer. 30 Aug 2009
• Effectiveness of two opioid antagonists in treating opioid-induced constipation. 30 Aug 2009
• Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. 10 Aug 2009
• [Preventing weight gain in smoking cessation: there is no miracle solution] 3 Aug 2009
• Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context. Aug 2009
• Appetitive motivational experience during adolescence results in enhanced alcohol consumption during adulthood. 30 Jul 2009
• Opioid antagonists block the acquisition of ethanol-mediated conditioned tactile preference in infant rats. 30 Jul 2009
• Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells. 30 Jul 2009
• Methylnaltrexone: new drug. Opiate-induced constipation: barely more effective than placebo. 30 Jul 2009
• Targeted naltrexone for problem drinkers. 30 Jul 2009
• Naltrexone for the treatment of obesity: review and update. 30 Jul 2009
• Effects of dehydroepiandrosterone sulfate on the conversion of corticosterone into 11-dehydrocorticosterone in stress: a regulatory scheme. 19 Jul 2009
• Delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway. 16 Jul 2009
• Methylnaltrexone. 13 Jul 2009
• Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. 13 Jul 2009

See a longer list of these articles.

Technical information about 'Naltrexone'

Definition: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Chemical name: Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-

Registry Number: 16590-41-3

Descriptor UI: D009271

Alternative terms: Naltrexone; Celupan; Lacer Brand of Naltrexone Hydrochloride; Trexan; Naltrexone Hydrochloride; Hydrochloride, Naltrexone; ReVia; Schering-Plough Brand of Naltrexone Hydrochloride; Schering Plough Brand of Naltrexone Hydrochloride; Lamepro Brand of Naltrexone Hydrochloride; United Drug Brand of Naltrexone Hydrochloride; Orphan Brand of Naltrexone Hydrochloride; Nemexin; Bristol-Myers Squibb Brand of Naltrexone Hydrochloride; Bristol Myers Squibb Brand of Naltrexone Hydrochloride; Du Pont Brand of Naltrexone Hydrochloride; Nalorex; Antaxone; Pharmazam Brand of Naltrexone Hydrochloride; EN-1639A; EN 1639A; EN1639A;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Narcotic Antagonists;

Tree Number: D03.132.577.249.706.550; D03.549.686.750.550; D03.605.497.750.550; D04.615.723.795.706.550;

History Note: 86(76); was see under NALOXONE 1976-85